Skip to content
Clinical Trials – home
Not yet recruiting

Phase II study of carboplatin, etoposide and tarlatamab re‑challenge in patients with relapsed extensive‑stage small cell lung cancer progressing during tarlatamab therapy

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on patients with small-cell lung cancer that has returned after initial treatment and spread widely (relapsed extensive disease). The investigational drug being used is tarlatamab, a therapy given by intravenous infusion. If the cancer shows signs of growing again while on this drug, the protocol calls for a repeat course of standard chemotherapy drugs, specifically carboplatin and etoposide, also delivered by infusion.

The purpose of the study is to determine whether giving the standard chemotherapy again after progression on tarlatamab can control the disease. Participants will first receive the investigational drug; if their disease progresses, they will start a series of chemotherapy cycles with the two standard drugs. Each cycle consists of a short hospital visit for the infusion followed by a recovery period, and patients will be monitored for side effects such as immune reactions (known as CRS) and neurological symptoms (ICANS).

Patients will be followed for several months to assess how long the disease stays stable without worsening, a measure called progression-free survival, which reflects the time from the start of the chemotherapy repeat until the cancer grows again. Additional assessments include overall survival, the proportion of patients whose tumors shrink (response rate), and the safety of the treatment. Tumor changes are evaluated using standard imaging criteria referred to as RECIST, which provides a consistent way to measure tumor size and response.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Assessments

    After joining the study, you will undergo a series of examinations, including physical checks, blood tests, and imaging scans, to document the current status of your small‑cell lung cancer.

    These assessments create a reference point for later comparisons during the trial.

  2. Step 2

    Initial Tarlatamab Infusion

    You will receive tarlatamab as a solution for infusion.

    The dose is 10 mg per infusion, administered intravenously according to the study schedule.

  3. Step 3

    Monitoring for Disease Progression

    Following each tarlatamab infusion, you will have regular follow‑up visits that include clinical evaluation and imaging to determine whether the cancer is stable or shows signs of progression.

    The frequency of these visits follows the protocol established by the investigators.

  4. Step 4

    Re‑challenge with Platinum‑Based Chemotherapy

    If the cancer progresses while you are receiving tarlatamab, the next step is a chemotherapy re‑challenge using two drugs:

    Carboplatin: 750 mg given as an intravenous infusion.

    Etoposide: 100 mg per square meter of body‑surface area, also given as an intravenous infusion.

    Both medications are administered according to the study’s cycle schedule, which is defined by the investigators.

  5. Step 5

    Ongoing Safety and Efficacy Monitoring

    During the chemotherapy cycles, you will continue to have clinical assessments, laboratory tests, and imaging to evaluate how the cancer responds and to monitor for side effects.

    Any adverse events, dose interruptions, or dose reductions will be recorded and managed as described in the trial protocol.

  6. Step 6

    Completion of Treatment and Follow‑Up

    After the designated number of chemotherapy cycles, treatment will be concluded.

    You will enter a follow‑up period during which periodic evaluations will be performed to assess long‑term outcomes such as disease control and overall survival.

Who can join the trial?

22 criteria

  • You must be at least 18 years old and be able to sign a written informed consent form yourself; a legal representative cannot give consent for you.
  • You must be willing and able to follow all study visits, examinations, and treatment schedules.
  • Your overall health must allow you to carry out daily activities with little or no limitation (known as an ECOG performance status of 0 or 1).
  • You need to have a life expectancy of at least 12 weeks (about 3 months) at the time you join the study.
  • You must have a confirmed diagnosis of locally advanced or metastatic small‑cell lung cancer (SCLC) based on tissue testing (histology or cytology) that cannot be cured with standard radiation‑chemo.
  • Your cancer must have progressed or come back after first‑line platinum‑based chemotherapy, and at least 90 days must have passed since the last platinum dose (this is called a platinum‑free interval of ≥ 90 days).
  • You must have already tried, or be unable to receive, a PD‑L1 inhibitor treatment.
  • Scans (CT or MRI) must show that your disease is getting worse while you are receiving tarlatamab, with or without a PD‑L1 inhibitor.
  • A new tumor tissue sample (biopsy) must be taken after your disease progresses on tarlatamab, unless a recent stored sample is already available or the study team agrees otherwise.
  • A tumor sample taken before your first‑line treatment must be provided to the study sponsor, or the sponsor must be consulted if it is not available.
  • The time between your last dose of tarlatamab and the first dose of the study treatment must be no more than 28 days; you may continue tarlatamab during the screening period, but no PD‑L1 inhibitor may be given after the first study day.
  • You need a recent imaging scan (CT or MRI) done within 28 days before enrollment, using slices no thicker than 5 mm and with contrast dye.
  • Your disease must be measurable on scans according to the standard criteria called RECIST 1.1.
  • Your blood and organ tests must show adequate function:
    • Hemoglobin (a measure of red blood cells) ≥ 9 g/dL
    • Absolute neutrophil count (a type of white blood cell) ≥ 1.5 × 10⁹/L
    • Platelet count ≥ 100 × 10⁹/L
    • Liver enzymes (AST/ALT) ≤ 2.5 times the normal upper limit (or ≤ 5 times if you have liver metastases)
    • Kidney function (creatinine clearance) > 41 mL/min
    • If you are a woman who could become pregnant, you must have a negative pregnancy test, use an effective method of birth control during the study and for 2 months after the last tarlatamab dose and for 6 months after the last carboplatin/etoposide dose, and you must not donate eggs.
    • If you are a woman who cannot become pregnant (post‑menopausal or pre‑menarchal), no birth control is required.
    • If you are a man who has a partner who could become pregnant, you must use a condom with spermicide for the entire study period, your partner must also use effective birth control, and you must not donate sperm.
    • All participants, regardless of sex, must agree to follow the contraception requirements and must not donate reproductive cells during the study and for the specified time after treatment.

Who cannot join the trial?

18 criteria

  • Having brain (central nervous system) metastases that cause symptoms, are not medically stable, or have had whole‑brain radiation or brain surgery too recently (less than 2 weeks after radiation or less than 7 days after stereotactic radiosurgery), or still needing steroids for brain disease.
  • Being HIV‑positive and not on effective antiretroviral therapy (ART), having changed ART within the last 6 months, using ART that could interfere with the study drugs, having a CD4‑cell count below 350 cells/µL, having had an AIDS‑defining infection in the past 6 months, or unwilling to start ART and achieve a low viral load.
  • Having a history of solid organ transplantation (such as a kidney, liver, or heart transplant).
  • Using immunosuppressive medicines within 7 days before the first dose, except for low‑dose steroids, inhaled or topical steroids, or steroids given only as pre‑medication for scans.
  • Having undergone major surgery within 4 weeks before starting the study and not having fully recovered, or expecting to need another major surgery during the study.
  • Taking any herbal or prescription medicines that block the body’s P‑glycoprotein (P‑gp) or breast cancer resistance protein (BCRP) transporters within 7 days before the first dose.
  • Taking any herbal or prescription medicines that strongly or moderately inhibit the liver enzyme cytochrome P450 3A (CYP3A) within 7 days before the first dose.
  • Taking any herbal or prescription medicines that strongly or moderately increase the activity of the CYP3A enzyme within 28 days before the first dose.
  • Receiving a live‑virus treatment or a live‑attenuated vaccine within 14 days before the first dose, or receiving any vaccine (including inactive ones) within 3 days before the first dose.
  • Currently participating in another investigational drug or device study, or having finished another such study less than 30 days ago.
  • Having a history of leptomeningeal carcinomatosis (cancer spread to the thin membranes covering the brain and spinal cord).
  • Being allergic or hypersensitive to any of the study drugs or to any inactive ingredients (excipients) in those drugs.
  • Having any unresolved side effect from previous cancer treatment that is graded 2 or higher on the National Cancer Institute’s toxicity scale (except for hair loss, vitiligo, taste changes, stable hypothyroidism, or certain nerve problems evaluated individually).
  • Having had another primary cancer within the past 2 years, unless it was treated curatively and meets specific low‑risk exceptions (such as certain skin cancers, in‑situ cancers, or localized prostate cancer with low recurrence risk).
  • Having any acute, chronic, or uncontrolled medical, mental, or psychological condition that could prevent safe participation or understanding of the study, such as uncontrolled infection, uncontrolled diabetes, uncontrolled seizures, superior vena cava syndrome, ongoing infection requiring systemic antibiotics (e.g., tuberculosis), interstitial lung disease, or severe psychiatric illness.
  • Having a history of significant heart or blood‑vessel disease, including pericarditis (inflammation of the heart lining), a heart attack within the last 3 months, symptomatic heart failure, uncontrolled high blood pressure, unstable chest pain (angina), unstable myocarditis (heart muscle inflammation), an abnormal resting ECG indicating serious heart problems, or a prolonged QT interval (QTc ≥ 470 ms) on baseline heart tests.
  • Having an active primary immunodeficiency (a condition that weakens the immune system).
  • Having an active hepatitis infection at screening: a positive hepatitis C antibody, a positive hepatitis B surface antigen, or a positive hepatitis B core antibody without meeting the study’s criteria for resolved infection.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • IMDYLLTRA

    is an investigational medicine called tarlatamab. It is given through a vein as a liquid and is designed to help the immune system recognize and attack small‑cell lung cancer cells. In this study, patients receive IMDYLLTRA while their disease is being monitored, and the drug’s effect on the cancer is evaluated.

  • Carboplatin

    is a chemotherapy drug that belongs to the platinum‑based class. It is given by infusion into a vein and works by damaging the DNA of cancer cells, which prevents them from growing and dividing. In this trial, carboplatin is used again (re‑challenge) to treat patients whose cancer has progressed while they were on IMDYLLTRA.

  • Etoposide

    is another chemotherapy medication given through an intravenous infusion. It interferes with the ability of cancer cells to copy their DNA, leading to cell death. In the trial, etoposide is combined with carboplatin as a re‑challenge therapy for patients whose disease has gotten worse during treatment with IMDYLLTRA.

What is already known about the treatment

  • Tarlatamab

    This drug is given as a powder that is mixed with liquid to create an intravenous infusion. It is still an experimental medicine and has orphan‑drug status while being studied in clinical trials. It is being tested for use in relapsed extensive‑stage small‑cell lung cancer. Tarlatamab works as a bispecific antibody that attaches to a protein called DLL3 on cancer cells and to CD3 on T‑cells, directing the immune cells to attack the tumor; it belongs to the class of bispecific T‑cell engager immunotherapies.

  • Carboplatin

    Carboplatin is supplied as a sterile solution for intravenous infusion. It is an approved, widely used chemotherapy drug that is listed in medical references. It is used to treat cancers such as small‑cell lung cancer, ovarian cancer, and others. The drug contains platinum, which binds to DNA and creates cross‑links that stop cancer cells from copying their genetic material; it is classified as a platinum‑based alkylating‑like chemotherapy agent.

  • Etoposide

    Etoposide comes as a concentrate that is mixed with fluid for intravenous infusion. It is an established, approved anticancer medication found in standard treatment guidelines. It is used for small‑cell lung cancer, testicular cancer, and certain other tumors. The medicine blocks an enzyme called topoisomerase II, causing breaks in DNA that lead to cancer cell death; it belongs to the class of topoisomerase II inhibitor cytotoxic chemotherapy.

Investigated diseases

Relapsed extensive-stage small-cell lung cancer - It is a fast‑growing cancer that starts in the small cells of the lung and has already spread beyond the lung at the time it is first diagnosed. After an initial response to therapy, the cancer can return, which is described as relapsed disease. When it returns, the tumor often regrows in the chest and may spread to the liver, brain, bones, or lymph nodes. The disease tends to progress rapidly, with new tumor sites appearing over weeks to months. Symptoms may worsen as the tumor burden increases, leading to cough, shortness of breath, and fatigue.
Trial detailsLast updated 22 Nov 2026
Age18+ yearsPhasePhase IITrial ID2026-527103-17-00Protocol codeUni-Koeln-5608Estimated enrolment54 patientsSponsorUniversity Of Cologne

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.